Overview
- The CNIO-led study found complete, durable remissions of pancreatic ductal adenocarcinoma in genetically engineered mice and in patient-derived xenografts.
- Targeting KRAS, EGFR and STAT3 simultaneously blocked resistance pathways, with no significant weight loss, blood abnormalities or organ damage reported in treated animals.
- The regimen combined a daraxonrasib-family KRAS inhibitor, the EGFR inhibitor afatinib and the STAT3 degrader SD36.
- In one patient-derived xenograft cohort, 16 of 18 mice remained disease-free about 200 days after stopping therapy.
- Researchers launched the start-up Vega Oncotargets to develop human-use candidates, estimating roughly €30 million for a phase 1 trial and noting regulatory uncertainties for EGFR and STAT3 agents.